Advertisement

Psychosis and Physical Comorbidity

  • Mary V. SeemanEmail author
Reference work entry
  • 8 Downloads
Part of the Mental Health and Illness Worldwide book series (MHIW)

Abstract

The life expectancy of men and women who suffer from psychotic illnesses is substantially shorter than that of the general population, with 90% of deaths attributable to the sequelae of physical illness. Suicide, accidents, and homicide account for the remaining 10%. Many of the responsible physical illnesses are brought on by heavy smoking, drinking, and lack of activity in the lives of individuals with psychosis. Some of the comorbidity may arise from psychotic illnesses sharing susceptibility genes with seemingly unrelated physical illnesses. Many diseases result from the adverse effects of antipsychotic treatment. It is also reported that the high mortality is due, to some degree, to delays in diagnosis and treatment for which physician stigmatization of mental illness is partially to blame. In many of the comorbid conditions, men and women are unequally affected. This chapter reviews the physical illnesses that complicate the lives of individuals with psychosis and suggests that the responsibility for preventing them is shared among patients, healthcare providers, and health systems. New ways of approaching this escalating problem are urgently needed.

Keywords

Schizophrenia Comorbidity Antipsychotics Prevention Integrated care 

References

  1. Attar R, Johansen MB, Valentin JB, Aagaard J, Jensen SE (2017) Treatment following myocardial infarction in patients with schizophrenia. PLoS One.  https://doi.org/10.1371/journal.pone.0189289
  2. Bailly-Salin P (2006) The mentally ill under nazi occupation in France. Int J Ment Health 35:11–35CrossRefGoogle Scholar
  3. Barker LC, Kurdyak P, Jacob B, Vigod SN (2018) Quality of diabetes care for individuals with comorbid chronic psychotic illness: a sex-based analysis. J Women’s Health 27:290–296CrossRefGoogle Scholar
  4. Bassett AS, Chow EWC, Weksberg R (2000) Chromosomal abnormalities and schizophrenia. Am J Med Genet 97:5–51CrossRefGoogle Scholar
  5. Bernard V, Young J, Binart N (2019) Prolactin – a pleiotropic factor in health and disease. Nat Rev Endocrinol.  https://doi.org/10.1038/s41574-019-0194-6. [Epub ahead of print]
  6. Bjornestad J, Davidson L, Joa I, Larsen TK, Hegelstad WTV, Langeveld J et al (2017) Antipsychotic treatment: experiences of fully recovered service users. J Ment Health 26:264–270CrossRefGoogle Scholar
  7. Blazer D (2018) Hearing loss: the silent risk for psychiatric disorders in late life. Psychiatr Clin N Am 41:19–27CrossRefGoogle Scholar
  8. Carson CM, Phillip N, Miller BJ (2017) Urinary tract infections in children and adolescents with acute psychosis. Schizophr Res 183:36–40CrossRefGoogle Scholar
  9. Chen SJ, Chao YL, Chen CY, Chang CM, Wu EC, Yeh HH et al (2012) Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. Br J Psychiatry 200:374–380CrossRefGoogle Scholar
  10. Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR (2014) The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry 14:75CrossRefPubMedPubMedCentralGoogle Scholar
  11. Correll CU, Detraux J, De Lepeleire J, De Hert M (2015) Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14:119–136CrossRefPubMedPubMedCentralGoogle Scholar
  12. Correll CU, Rubio JM, Kane JM (2018) What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 17:149–160CrossRefPubMedPubMedCentralGoogle Scholar
  13. Curhan SG, Eliassen AH, Eavey RD, Wan M, Lin BM, Curhan GC (2017) Menopause and postmenopausal hormone therapy and risk of hearing loss. Menopause 24:1049–1056CrossRefPubMedPubMedCentralGoogle Scholar
  14. Darpo B, Karnad DR, Badilini F, Florian J, Garnett CE, Kothari S et al (2014) Are women more susceptible than men to drug-induced QT prolongation? Concentration–QTc modelling in a phase 1 study with oral rac-sotalol. Br J Clin Pharmacol 77:522–531CrossRefPubMedPubMedCentralGoogle Scholar
  15. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I et al (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10:52–77CrossRefGoogle Scholar
  16. Dekker JJM, Theunissen J, Van R, Peen J, Duurkoop P, Kikkert M (2010) Victimization of patients with severe psychiatric disorders: prevalence, risk factors, protective factors and consequences for mental health. A longitudinal study. BMC Pub Health 10:687CrossRefGoogle Scholar
  17. Dornquast C, Tomzik J, Reinhold T, Walle M, Mönter N, Berghöfer A (2017) To what extent are psychiatrists aware of the comorbid somatic illnesses of their patients with serious mental illnesses? – a cross-sectional secondary data analysis. BMC Health Serv Res 17:162CrossRefPubMedPubMedCentralGoogle Scholar
  18. Eaton WE, Mortensen PB, Agerbo E, Byrne M, Mors O, Ewald H (2004) Coeliac disease and schizophrenia: population based case control study with linkage of Danish national registers. BMJ 328:438–439CrossRefPubMedPubMedCentralGoogle Scholar
  19. Eaton WW, Byrne M, Ewald H, Mors O, Agerbo E, Mortensen PB (2006) Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 163:521–528CrossRefGoogle Scholar
  20. Ehrlich C, Chester P, Kisely S, Crompton D, Kendall E (2018) Making sense of self-care practices at the intersection of severe mental illness and physical health – an Australian study. Health Soc Care Community 26:e47–e55CrossRefPubMedPubMedCentralGoogle Scholar
  21. Eskelinen S, Sailas E, Joutsenniemi K, Holi M, Koskela TH, Suvisaari J (2017) Multiple physical healthcare needs among outpatients with schizophrenia: findings from a health examination study. Nord J Psychiatry 71:448–454CrossRefPubMedPubMedCentralGoogle Scholar
  22. González-Rodríguez A, Catalán R, Penadés R, Ruiz Cortés VBN, Torra M, Seeman MV et al (2016) Antipsychotic response worsens with postmenopausal duration in women with schizophrenia. J Clin Psychopharmacol 36:580–587CrossRefGoogle Scholar
  23. Goubert L, Trompetter H (2017) Towards a science and practice of resilience in the face of pain. Eur J Pain 21:1301–1315CrossRefGoogle Scholar
  24. Green S, Beveridge E, Evans L, Trite J, Jayacodi S, Evered R et al (2018) Implementing guidelines on physical health in the acute mental health setting: a quality improvement approach. Int J Ment Health Syst 12:1CrossRefPubMedPubMedCentralGoogle Scholar
  25. Griswold KS, Del Regno PA, Berger RC (2015) Recognition and differential diagnosis of psychosis in primary care. Am Fam Physician 91:856–863PubMedPubMedCentralGoogle Scholar
  26. Guerreiro DF, Navarro R, Silva M, Carvalho M, Gois C (2009) Psychosis secondary to traumatic brain injury. Brain Inj 23:358–336CrossRefPubMedPubMedCentralGoogle Scholar
  27. Heald A, Livingston M, Yung A, De Hert MA (2017) Prescribing in schizophrenia and psychosis: increasing polypharmacy over time. Hum Psychopharmacol 32:e2579CrossRefGoogle Scholar
  28. Heinrich TW, Grahm G (2003) Hypothyroidism presenting as psychosis: myxedema madness revisited. Prim Care Companion J Clin Psychiatry 5:260–266CrossRefPubMedPubMedCentralGoogle Scholar
  29. Hochner-Celnikier D, Manor O, Garbi B, Chajek-Shaul T (2005) Gender gap in cerebrovascular accidents: comparison of the extent, severity, and risk factors in men and women aged 45–65. Int J Fertil Womens Med 50:122–128PubMedPubMedCentralGoogle Scholar
  30. Horvitz-Lennon M, Kilbourne AM, Pincus HA (2006) From silos to bridges: meeting the general health care needs of adults with severe mental illnesses. Health Aff 25:659–669CrossRefGoogle Scholar
  31. Ittig S, Studerus E, Heitz U, Menghini-Müller S, Beck K, Egloff L et al (2017) Sex differences in prolactin levels in emerging psychosis: indication for enhanced stress reactivity in women. Schizophr Res 189:111–116CrossRefPubMedPubMedCentralGoogle Scholar
  32. Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, Gardsjord ES et al (2017) Side effect burden of antipsychotic drugs in real life – impact of gender and polypharmacy. Prog Neuro-Psychopharmacol Biol Psychiatry 82:263–271CrossRefGoogle Scholar
  33. Jia JM, Zhao J, Hu Z, Lindberg D, Li Z (2013) Age-dependent regulation of synaptic connections by dopamine D2 receptors. Nat Neurosci 16:1627–1636CrossRefPubMedPubMedCentralGoogle Scholar
  34. Jung SY, Park JW, Kim DH, Jun YH, Lee JS, Lee JE (2014) Mosaic turner syndrome associated with schizophrenia. Ann Pediatr Endocrinol Metab 19:42–44CrossRefPubMedPubMedCentralGoogle Scholar
  35. Khalifeh H, Moran P, Borschmann R, Dean K, Hart C, Hogg J et al (2015) Domestic and sexual violence against patients with severe mental illness. Psychol Med 45:875–886CrossRefGoogle Scholar
  36. Marriott I, Huet-Hudson YM (2006) Sexual dimorphism in innate immune responses to infectious organisms. Immunol Res 34:177–192CrossRefGoogle Scholar
  37. McKee AC, Daneshvar DH (2015) The neuropathology of traumatic brain injury. Handb Clin Neurol 127:45–66CrossRefPubMedPubMedCentralGoogle Scholar
  38. Meade CS, Sikkema KJ (2005) Voluntary HIV testing among adults with severe mental illness: frequency and associated factors. AIDS Behav 9:465–473CrossRefGoogle Scholar
  39. Mendrek A, Fattore L (2017) Sex differences in drug-induced psychosis. Curr Opin Behav Sci 13:152–157CrossRefGoogle Scholar
  40. Moore S, Shiers D, Daly B, Mitchell AJ, Gaughran F (2015) Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care. Acta Psychiatr Scand 132:109–121CrossRefGoogle Scholar
  41. Niemi LT, Suvisaari JM, Tuulio-Henriksson A, Lönnqvist JK (2003) Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophr Res 60:239–258CrossRefGoogle Scholar
  42. Oram S, Khalifeh H, Howard LM (2016) Violence against women and mental health. Lancet Psychiatry 4:159–170CrossRefGoogle Scholar
  43. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S et al (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64:19–28CrossRefGoogle Scholar
  44. Rademaker M (2001) Do women have more adverse drug reactions? Am J Clin Dermatol 2:349–351CrossRefGoogle Scholar
  45. Rado J (2017) The complex inter-relationship between diabetes and schizophrenia. Curr Diabetes Rev 13:195–212CrossRefGoogle Scholar
  46. Rasolofo-Razanamparany V, Menard D, Ratsitorahina M, Auregan G, Gicquel B, Chanteau S (2000) Transmission of tuberculosis in the prison of Antananarivo (Madagascar). Res Microbiol 151:785–795CrossRefGoogle Scholar
  47. Reddy DS (2014) Neurosteroids and their role in sex-specific epilepsies. Neurobiol Dis 72(PtB): 198–209CrossRefGoogle Scholar
  48. Reeve S, Emsley R, Sheaves B, Freeman D (2018) Disrupting sleep: the effects of sleep loss on psychotic experiences tested in an experimental study with mediation analysis. Schizophr Bull 44:662–671PubMedGoogle Scholar
  49. Riecher-Rössler A (2017) Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. Lancet Psychiatry 4:63–72CrossRefPubMedPubMedCentralGoogle Scholar
  50. Riecher-Rössler A, Löffler W, Munk-Jørgensen P (1997) What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci 247:195–208CrossRefPubMedPubMedCentralGoogle Scholar
  51. Sahoo S, Grover S (2016) Hyponatremia and psychotropics. J Geriatr Ment Health 3:108–122CrossRefGoogle Scholar
  52. Seeman P (2011) All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS Neurosci Therap 17:118–132CrossRefGoogle Scholar
  53. Seeman MV (2012) Antipsychotic-induced somnolence in mothers with schizophrenia. Psychiatry Q 83:83–89CrossRefGoogle Scholar
  54. Seeman MV (2015) The role of mental health services in addressing HIV infection among women with serious mental illness. Psychiatr Serv 66:966–974CrossRefPubMedPubMedCentralGoogle Scholar
  55. Seeman MV (2017) Breast cancer prevention and treatment in women with severe mental illness. Int J Womens Health Wellness 3:064Google Scholar
  56. Severance EG, Yolken RH, Eaton WW (2016) Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr Res 176:23–35CrossRefGoogle Scholar
  57. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M et al (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 13:757–777CrossRefPubMedPubMedCentralGoogle Scholar
  58. Sørensen HJ, Nielsen PR, Benros ME, Pedersen CB, Mortensen PB (2015) Somatic diseases and conditions before the first diagnosis of schizophrenia: a nationwide population-based cohort study in more than 900 000 individuals. Schizophr Bull 41:513–521CrossRefGoogle Scholar
  59. Tenback DE, van Harten PN (2011) Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol 98:211–230CrossRefPubMedPubMedCentralGoogle Scholar
  60. Torrey EF, Yolken RH (2017) Schizophrenia and infections: the eyes have it. Schizophr Bull 43:247–252PubMedPubMedCentralGoogle Scholar
  61. Turrone P, Seeman MV, Silvestri S (2000) Estrogen receptor activation and tardive dyskinesia. Can J Psychiatr 45:288–290CrossRefGoogle Scholar
  62. Ungar T, Goldman S, Marcus M (2013) Reversed shared care in mental health: bringing primary physical health care to psychiatric patients. Can J Commun Ment Health 32:1–16CrossRefGoogle Scholar
  63. Walker ER, McGee RE, Druss BG (2015) Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiat 72:334–341CrossRefGoogle Scholar
  64. Wang MT, Tsai CL, Lin CW, Yeh CB, Wang YH, Lin HL (2017) Association between antipsychotic agents and risk of acute respiratory failure in patients with chronic obstructive pulmonary disease. JAMA Psychiat 74:252–260CrossRefGoogle Scholar
  65. Yarborough BJH, Stumbo SP, Perrin NA, Hanson GC, Muench J, Green CA (2018) Effects of primary care clinician beliefs and perceived organizational facilitators on the delivery of preventive care to individuals with mental illnesses. BMC Fam Pract 19:16CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Department of PsychiatryUniversity of TorontoTorontoCanada

Personalised recommendations